Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis

Al-Azhar University

Status: Enrolling

Conditions: Nocturnal Enuresis

Treatments: Drug: Desmopressin

Study type: Interventional

Funder types: Other

Identifiers

NCT06285006

MScAZASTPED025/23/202/12/2021

Details and patient eligibility

About

Nocturnal Enuresis (NE) is defined as the involuntary passage of urine during sleep past the age of usual control, which is considered a developmental age of 5 to 7 years.

NE is a common problem that causes distress to both children and their families. It has an adverse impact on behavior and social life, affects self-esteem, and can result in poor emotional well-being. In Egypt, the prevalence of NE in primary school children is about 15.4%. The family history was seen to have had a markedly significant impact on the occurrence of NE in the studied children. The mainstay of treatment is urotherapy with information and psychoeducation about normal lower urinary tract function, the underlying cause of MNE, disturbed bladder dysfunction in the child with NMNE, and instructions about therapeutic strategies. Alarm therapy and desmopressin are effective in randomized trials. Children with NMNE first need treatment of the underlying daytime functional bladder problem before treatment of nocturnal enuresis.

Enrollment: 50 estimated patients

Sex: All

Ages: 7 to 14 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• School age group (from 7 to 14 years)
• Primary monosymptomatic nocturnal enuresis

Exclusion criteria

Patients with one or more of the following will be excluded from the study.

• Diurnal enuresis
• Urinary tract infection within the preceding 3 months
• Diabetes mellitus
• History of renal disease, hypertension or genitourinary abnormality, neurological disease, or psychological disease.
• Post-micturition residual urine >1/3 expected bladder capacity.
• Each patient will be subjected to the following.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

Desmopressin

Experimental group

Description:

Desmopressin is a synthetic analogue of ADH released by the posterior pituitary gland that reduces urine production by increasing water reabsorption by the collecting tubules.

Treatment:

Drug: Desmopressin